References
- Tartaglia NR, Howell S, Sutherland A, et al. A review of trisomy X (47,XXX). Orphanet J Rare Dis 2010;5:8
- Panduragi M, Tamizharasi M, Sanjeeva Reddy N. Pregnancy outcome of assisted reproductive technology cycle in patients with hypogonadotropic hypogonadism. J Human ReprodSci 2015;8:146–50
- La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113–30
- La Marca A, Giulini S, Orvieto R, et al. Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 2005;20:1569–72
- Mohamed KA, Davies WA, Lashen H. Antimullerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. FertilSteril 2006;86:1515–17
- Tran ND, Cedars MI, Rosen MP. The role of anti-mullerian hormone (AMH) in assessing ovarian reserve. J Clin Endocrinol Metab 2011;96:3609–14
- Yasmine E, Davies M, Conway G, Balen AH. British fertility society: “ovulation induction in WHO type 1 anovulation: guidelines for practice” produced on behalf of the BFS policy and practice committee. Human Fertil 2013;16:228–34
- Yilmaz S, Ozgu-Erdinc AS, Ymusak O, et al. The reproductive outcome of women with hypogonadotropic hypogonadiasm undergoing in vitro fertilization. Syst Biol Reprod Med 2015;61:228–32
- Fiorio P, Rosaia De Santis L, Cuoco C, et al. Hypogonadotropic hypogonadism in a trisomy X carrier: phenotype description and genotype correlation. Gynecol Endocrinol 2016;32:14–17